136 related articles for article (PubMed ID: 21906698)
1. Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab')2 against highly pathogenic avian influenza H5N1 in mice.
Zhao Z; Yan F; Chen Z; Luo D; Duan Y; Yang P; Li Z; Peng D; Liu X; Wang X
Int Immunopharmacol; 2011 Dec; 11(12):2000-6. PubMed ID: 21906698
[TBL] [Abstract][Full Text] [Related]
2. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.
Lu J; Guo Z; Pan X; Wang G; Zhang D; Li Y; Tan B; Ouyang L; Yu X
Respir Res; 2006 Mar; 7(1):43. PubMed ID: 16553963
[TBL] [Abstract][Full Text] [Related]
3. Specific polyclonal F(ab')2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice.
Herbreteau CH; Jacquot F; Rith S; Vacher L; Nguyen L; Carbonnelle C; Lotteau V; Jolivet M; Raoul H; Buchy P; Saluzzo JF
Immunotherapy; 2014; 6(6):699-708. PubMed ID: 24673720
[TBL] [Abstract][Full Text] [Related]
4. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
5. Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine.
Yang P; Tang C; Luo D; Zhan Z; Xing L; Duan Y; Jia W; Peng D; Liu X; Wang X
Vet Microbiol; 2010 Nov; 146(1-2):17-23. PubMed ID: 20888151
[TBL] [Abstract][Full Text] [Related]
6. Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study.
Bal C; Herbreteau CH; Buchy P; Rith S; Zaid M; Kristanto W; Han V; Reynaud C; Granjard P; Lépine B; Durand C; Tambyah PA
Lancet Infect Dis; 2015 Mar; 15(3):285-92. PubMed ID: 25662592
[TBL] [Abstract][Full Text] [Related]
7. Protection from infection with influenza A H7N9 virus in a mouse model by equine neutralizing F(ab')2.
Zhao Z; Fan C; Duan Y; Zhang L; Li M; Yang X; Li R; Yang P; Wang X
Int Immunopharmacol; 2014 Nov; 23(1):134-8. PubMed ID: 25192652
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza.
Prabhu N; Prabakaran M; Hongliang Q; He F; Ho HT; Qiang J; Goutama M; Lim AP; Hanson BJ; Kwang J
Antivir Ther; 2009; 14(7):911-21. PubMed ID: 19918095
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets.
Song MS; Oh TK; Pascua PN; Moon HJ; Lee JH; Baek YH; Woo KJ; Yoon Y; Sung MH; Poo H; Kim CJ; Choi YK
Vaccine; 2009 May; 27(24):3145-52. PubMed ID: 19446184
[TBL] [Abstract][Full Text] [Related]
10. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
Crevar CJ; Ross TM
Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
[TBL] [Abstract][Full Text] [Related]
11. [Effects of immunoglobulin on murine myocarditis caused by influenza A virus: experimental study].
Kishimoto C; Hiraoka Y; Takada H; Kurokawa M; Ochiai H
J Cardiol; 2005 Jun; 45(6):247-55. PubMed ID: 15991608
[TBL] [Abstract][Full Text] [Related]
12. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.
Park KS; Lee J; Ahn SS; Byun YH; Seong BL; Baek YH; Song MS; Choi YK; Na YJ; Hwang I; Sung YC; Lee CG
Virology; 2009 Dec; 395(2):182-9. PubMed ID: 19836045
[TBL] [Abstract][Full Text] [Related]
13. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
[TBL] [Abstract][Full Text] [Related]
14. Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.
Yang P; Duan Y; Zhang P; Li Z; Wang C; Dong M; Tang C; Xing L; Gu H; Zhao Z; Liu X; Zhang S; Wang X
PLoS One; 2012; 7(1):e30252. PubMed ID: 22279575
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes.
Wu J; Zhang F; Fang F; Chang H; Wang F; Yang Z; Sun B; Chen Z
Vaccine; 2010 Mar; 28(15):2775-81. PubMed ID: 20117261
[TBL] [Abstract][Full Text] [Related]
17. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
18. Intranasal administration of a live non-pathogenic avian H5N1 influenza virus from a virus library confers protective immunity against H5N1 highly pathogenic avian influenza virus infection in mice: comparison of formulations and administration routes of vaccines.
Kashima Y; Ikeda M; Itoh Y; Sakoda Y; Nagata T; Miyake T; Soda K; Ozaki H; Nakayama M; Shibuya H; Okamatsu M; Ishigaki H; Ishida H; Sawai T; Kawaoka Y; Kida H; Ogasawara K
Vaccine; 2009 Dec; 27(52):7402-8. PubMed ID: 19747993
[TBL] [Abstract][Full Text] [Related]
19. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
Thueng-in K; Maneewatch S; Srimanote P; Songserm T; Tapchaisri P; Sookrung N; Tongtawe P; Channarong S; Chaicumpa W
Vaccine; 2010 Sep; 28(41):6765-77. PubMed ID: 20688037
[TBL] [Abstract][Full Text] [Related]
20. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]